Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3502MR)

This product GTTS-WQ3502MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3502MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1218MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ13203MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ11016MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ15613MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ12626MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15523MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ5972MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ15862MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW